Overview

A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

Status:
Recruiting

Trial end date:
2023-12-01

Target enrollment:
0

Participant gender:
All

Summary

This is a randomized, open-label, controlled, multicenter Phase III study to evaluate the effectiveness and safety of IBI310 combined with sintilimab and sorafenib in patients with locally advanced or metastatic HCC who have not previously received systemic therapy, are unsuitable for radical surgical resection or local treatment, or have had progressive disease after surgical resection or local treatment.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Innovent Biologics (Suzhou) Co. Ltd.

Treatments:

Sorafenib

Criteria

Inclusion Criteria:

1. Histologically/cytologically confirmed hepatocellular carcinoma, or liver cirrhosis
meeting the clinical diagnostic criteria;

2. ECOG performance status score of 0 or 1 point;

3. No systemic antitumor treatment for hepatocellular carcinoma before the first
administration;

4. Barcelona Clinic Liver Cancer stage C, or Stage B not suitable for radical surgery
and/or local treatment;

5. At least 1 measurable lesion according to RECIST V1.1);

6. Child-Pugh:≤6

7. Adequate organ and bone marrow function.

Exclusion Criteria:

1. With fibrous lamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma,
cholangiocarcinoma components in tumor tissues.

2. Have a history of hepatic encephalopathy or have a history of liver transplantation.

3. With clinical symptoms requires drainage of pleural effusion, ascites or pericardial
effusion.

4. Central nervous system (CNS) metastasis.

5. Uncontrolled high blood pressure, systolic blood pressure >140mmHg or diastolic blood
pressure >90mmHg after optimal medical treatment.

6. Local treatment for liver lesions within 4 weeks.